HANSOH PHARMA (03692.HK): Socrodeucitinib NDA accepted by NMPA for psoriasis
NewTimeSpace News: On November 20, 2026, HANSOH PHARMA (03692.HK) announced that the new drug application (NDA) for its innovative medicine Socrodeucitinib Tablets (HS-10374 Tablets) has been accepted by China's National Medical Products Administration (NMPA) for adult patients with moderate-to-severe plaque psoriasis.
According to the announcement, Socrodeucitinib Tablets is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2) self-developed by the Group, and the indication filed this time is moderate-to-severe plaque psoriasis in adults. Following acceptance, the product remains subject to the NMPA's review and approval procedures, and the announcement was published on a voluntary basis.
- HANSOH PHARMA (03692.HK): Almonertinib Wins Positive CHMP Opinion for EU Approval in NSCLC
- HANSOH PHARMA (03692.HK): AilsynBio Deal Gives Access to AI Platform for Oral Cyclic Peptides
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- HANSOH PHARMA (03692.HK): Signs ADC Strategic Collaboration and Licence with Roche; US$400mn Upfront, Over US$15bn Milestones